• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Immunol . The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophag

tetano

Editor, Senior Moderator
Nat Immunol


. 2024 Mar 7.
doi: 10.1038/s41590-024-01776-2. Online ahead of print. The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis

Xin He[SUP] #[/SUP][SUP] 1 [/SUP], Xiantao Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Bolin Wu[SUP] #[/SUP][SUP] 1 [/SUP], Jieyi Deng[SUP] #[/SUP][SUP] 1 [/SUP], Yongli Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Airu Zhu[SUP] #[/SUP][SUP] 2 3 [/SUP], Yaochang Yuan[SUP] 1 [/SUP], Yingtong Lin[SUP] 1 [/SUP], Achun Chen[SUP] 1 [/SUP], Jinzhu Feng[SUP] 1 [/SUP], Xiumei Wang[SUP] 1 [/SUP], Shijian Wu[SUP] 1 [/SUP], Yingying Liu[SUP] 1 [/SUP], Jie Liu[SUP] 1 [/SUP], Yalin Wang[SUP] 1 [/SUP], Rong Li[SUP] 1 [/SUP], Chaofeng Liang[SUP] 1 [/SUP], Quyu Yuan[SUP] 1 [/SUP], Yu Liang[SUP] 1 [/SUP], Qiannan Fang[SUP] 4 [/SUP], Zhihui Xi[SUP] 4 [/SUP], Wenjie Li[SUP] 1 [/SUP], Liting Liang[SUP] 5 [/SUP], Zhenglai Zhang[SUP] 2 [/SUP], Hui Tang[SUP] 1 [/SUP], Yi Peng[SUP] 1 [/SUP], Changwen Ke[SUP] 6 [/SUP], Xiancai Ma[SUP] 2 [/SUP], Weibin Cai[SUP] 7 [/SUP], Ting Pan[SUP] 1 8 [/SUP], Bingfeng Liu[SUP] 1 [/SUP], Kai Deng[SUP] 1 [/SUP], Jun Chen[SUP] 1 7 [/SUP], Jincun Zhao[SUP] 9 10 [/SUP], Xuepeng Wei[SUP] 11 [/SUP], Ran Chen[SUP] 12 [/SUP], Yiwen Zhang[SUP] 13 [/SUP], Hui Zhang[SUP] 14 15 [/SUP]



Affiliations
Abstract

The development of a vaccine specific to severe acute respiratory syndrome coronavirus 2 Omicron has been hampered due to its low immunogenicity. Here, using reverse mutagenesis, we found that a phenylalanine-to-serine mutation at position 375 (F375S) in the spike protein of Omicron to revert it to the sequence found in Delta and other ancestral strains significantly enhanced the immunogenicity of Omicron vaccines. Sequence FAPFFAF at position 371-377 in Omicron spike had a potent inhibitory effect on macrophage uptake of receptor-binding domain (RBD) nanoparticles or spike-pseudovirus particles containing this sequence. Omicron RBD enhanced binding to Siglec-9 on macrophages to impair phagocytosis and antigen presentation and promote immune evasion, which could be abrogated by the F375S mutation. A bivalent F375S Omicron RBD and Delta-RBD nanoparticle vaccine elicited potent and broad nAbs in mice, rabbits and rhesus macaques. Our research suggested that manipulation of the Siglec-9 pathway could be a promising approach to enhance vaccine response.


 
Back
Top Bottom